CD4 and lung adenocarcinoma: Tumor neoantigens recognized by TILs promote the crosstalk between tumor-specific CD4+ T cells and tumor-specific B cells, thus enhancing the anti-tumor immunity of CD8+ T cells in lung adenocarcinoma (LUAD) 80.